MedTrace Logo

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

NCT02344680 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 303

Last updated 2025-06-10

No results posted yet for this study

Summary

A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.

Conditions

  • Human Immunodeficiency Virus
  • HBV
  • Fibrosis, Liver
  • Cirrhosis, Liver
  • Hepatocellular Carcinoma
  • Hepatitis Delta Virus
  • Alcoholic Hepatitis

Interventions

DRUG

Anti-HIV Agents

Sponsors & Collaborators

  • Fogarty International Center of the National Institute of Health

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Michael J Vinikoor, MD · University of Alabama at Birmingham

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02344680 on ClinicalTrials.gov